Search | Clinical Trials Finder

Conditions: Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions: Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography; Procedure · Other · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 686 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2036
U.S. locations: 106
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastasis
Interventions: THOR-707, Checkpoint inhibitor, anti-EGFR antibody; Drug
Lead sponsor: Synthorx, Inc, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 7
States / cities: Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more

Conditions: Contingency Management, Methamphetamine Use Disorder
Interventions: Contingency management; Behavioral
Lead sponsor: Queen's Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: HIV Infections
Interventions: Atazanavir, Darunavir, Efavirenz, Nevirapine, Ritonavir, Tenofovir disoproxil fumarate, Pharmacokinetic Study; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 17 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 21
States / cities: Alhambra, California • La Jolla, California • Long Beach, California + 16 more

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876, Nivolumab, Ipilimumab; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more

Conditions: Healthy Volunteer
Interventions: Icovamenib, Icovamenib HPMC; Drug
Lead sponsor: Biomea Fusion Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hematologic Neoplasms
Interventions: Stem cell transplantation, Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, Prednisone, Methotrexate, Cyclosporine, Apheresis; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Interventions: Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure; Drug · Procedure · Other
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 97
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more

Conditions: Multiple Myeloma
Interventions: Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 7
States / cities: Encinitas, California • West Hills, California • West Hollywood, California + 4 more

Conditions: Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions: XL102, Fulvestrant, Abiraterone, Prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Atlanta, Georgia • Boston, Massachusetts • Dallas, Texas + 2 more

Conditions: Decrease of Proteinuria With H.P. Acthar Gel and Its Effects on Clinical and Podocyte Function
Interventions: Acthar; Drug
Lead sponsor: Greater Boston Medical Associates; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Milford, Massachusetts

Conditions: Infections, Bacterial
Interventions: Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: HIV-1 Infection, HCV Infection
Interventions: E/C/F/TAF, F/R/TAF, LDV/SOF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
Interventions: 9-ING-41, Irinotecan, Temozolomide, Cyclophosphamide, Topotecan; Drug
Lead sponsor: Actuate Therapeutics Inc.; Industry
Eligibility: Up to 22 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Aurora, Colorado • Chicago, Illinois + 6 more

Conditions: Amphetamine-related Disorders
Interventions: contingency management voucher; Behavioral
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: Los Angeles, California • Rancho Cucamonga, California

Conditions: Breast Cancer
Interventions: F-Var3 PET/CT, Blood draw; Diagnostic Test · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions: aflibercept, oxaliplatin, leucovorin, fluorouracil, Correlative Studies, DCE MRI, f18FDG-PET, PET (positron emission tomography); Biological · Drug · Other + 2 more
Lead sponsor: John Hays; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 6
States / cities: Ann Arbor, Michigan • Buffalo, New York • The Bronx, New York + 3 more

Conditions: Hematologic Neoplasms, Lymphoproliferative Disorders, Leukemia, Leukemia, Lymphocytic, Chronic
Interventions: Clofarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Failure
Interventions: Midazolam, Normal saline, Fentanyl; Drug
Lead sponsor: Javier Gelvez, MD; Other
Eligibility: Up to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Delinquency, Drug Use
Interventions: Treatment Foster Care (TFCO), Group Care; Behavioral
Lead sponsor: Oregon Social Learning Center; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2016
U.S. locations: 2
States / cities: Eugene, Oregon

Conditions: Pancreatic Cancer
Interventions: Proton radiation and chemotherapy; Radiation
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions: entinostat, Omeprazole, Famotidine; Drug · Dietary Supplement
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions: Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)

Implementing a Contingency Management Program Addressing Methamphetamine Use for and With the People of Hawai'i

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Food Effect Study in Healthy Volunteers

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Experience With H.P. Acthar Gel Treatment of Patients With Nephrotic Syndrome/Proteinuria Due to Various Etiologies and Its Effect on Podocyte Function

Drug-drug Interaction Study of Gepotidacin

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Long-term Behavior Change - 1

Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer

Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer

Clofarabine in Chronic Lymphocytic Leukemia

Cycling of Sedative Infusions in Critically Ill Pediatric Patients

Juvenile Justice Girls Randomized Control Trial: Young Adult Follow-up

Proton Therapy for Unresectable Cancer (CA) of Pancreas

A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy